Thus, different effects of GITR stimulation (activation of effectors or Tregs) can be used to reduce the immune response in ARDs, and the choice of a specific mechanism apparently depends on the specific state of the immune system. The gene discussed is TNFRSF18; the disease is acute respiratory distress syndrome.